ArticleBMC pediatrics2026
Burden of laboratory-confirmed RSV hospitalization in children <5 years-of-age; 2019-2022.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRespiratory Syncytial Virus (RSV) is one of the leading causes of acute lower respiratory tract infection (LRTI) in children. We sought to measure the clinical and economic burden of hospitalized RSV LRTI in children.
methodsWe conducted a prospective study of Salt Lake County resident children < 5 years hospitalized with laboratory-confirmed RSV LRTI (hospitalized > 24 h) from 2019 to 2022 at Primary Children's and Riverton Hospitals, Salt Lake City, Utah. Demographic, clinical, and hospital cost data were abstracted from the electronic medical records and financial transaction database.
resultsOverall, 637 children were hospitalized with laboratory-confirmed RSV infection; 43% <6 months, 36% 6-<24 months, and 21% 24-<60 months years of age. Median hospital LOS was 2.2 days (IQR: 1.6-3.7days) with median and mean hospital cost of $6126 (IQR: $3577-$13436) and $13,941 (SD $26,235) respectively. Admissions to ICU and intubation decreased with age (p < 0.01), while antibiotic, steroid, and bronchodilator use increased with age (p < 0.01). Hospitalization rates were 24.1, 16.4, 11.1 and 5.5 per 1,000 person-years among children < 6 months, < 1 year, < 2 years and 5 years respectively. Extrapolating to all US children, RSV is estimated to cause ∼101,000 annual hospitalizations nationwide, 63% in otherwise healthy children, with an average total hospital cost of $1.4 billion (95% CI, $683 million-$1.9 billion).
conclusionsHospitalized RSV continues to be associated with substantial clinical and cost burden. This underscores the urgent need for widespread implementation of RSV immunoprophylaxis strategies to reduce hospitalization rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.